Guardant Health

Corporate brand

Guardant Health is a United States precision-oncology and cancer-screening company that develops blood-based genomic tests and related data services.

Last updated November 4, 2026

AI crawler reads

No AI crawler has read this profile yet.

Overview

Guardant Health is a healthcare technology company focused on blood-based genomic testing, precision oncology, and population-scale cancer screening. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company was established around the idea that a blood sample can reveal clinically useful information about tumor DNA, including mutations that may help physicians select therapies, monitor treatment response, or detect residual disease. The company’s principal business has been oncology testing. Its Guardant360 platform analyzes circulating tumor DNA from a blood sample and is used in advanced cancer care to characterize genomic alterations and support treatment decisions. Guardant360 CDx is the company’s FDA-approved companion diagnostic version of the platform for selected targeted therapies. Guardant also offers tests intended to monitor molecular response and recurrence, including Guardant360 Response and Reveal. These products are designed for different clinical questions, such as identifying actionable alterations, assessing whether a tumor is responding to therapy, and detecting molecular residual disease after treatment. Guardant has also expanded into earlier detection and screening. Its Shield blood test is intended to screen adults at average risk for colorectal cancer by detecting cancer-associated signals in blood. The U.S. Food and Drug Administration approved Shield in 2024, making it one of the company’s most important efforts to move liquid biopsy beyond advanced-cancer management and into routine population screening. The company has described additional opportunities in multi-cancer early detection, although such programs remain subject to clinical validation, regulatory review, and adoption by healthcare systems. Its business combines laboratory-developed and regulated diagnostic tests, biopharmaceutical partnerships, clinical data, and software-enabled services. Guardant works with oncologists, health systems, biopharmaceutical companies, and researchers. Pharmaceutical companies use its testing and data capabilities in drug development, clinical-trial enrollment, biomarker research, and post-approval treatment monitoring. Guardant Health became a publicly traded company on Nasdaq in 2018. Its competitive position rests on its testing platforms, clinical evidence, relationships with healthcare providers and drug developers, and large longitudinal datasets derived from patient samples. The company operates in a market that includes other liquid-biopsy and molecular-diagnostics providers, such as Foundation Medicine, Natera, Exact Sciences, Caris Life Sciences, and several specialized sequencing companies. Its main strategic challenge is converting technical capability into routine reimbursement, physician adoption, and durable clinical utility while controlling laboratory and commercialization costs. Guardant Health remains an active, independent public company headquartered in Palo Alto, California. Its portfolio spans advanced cancer profiling, treatment monitoring, recurrence-risk assessment, colorectal-cancer screening, and data services supporting precision medicine.

History

Guardant Health was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz. The founders built the company around liquid biopsy, a method that analyzes fragments of tumor-derived DNA circulating in blood. Compared with tissue biopsy, a blood sample can be easier to obtain and may provide a repeatable way to study a tumor over time, although the sensitivity and clinical usefulness of testing vary by cancer type, disease burden, and clinical setting. Guardant initially concentrated on advanced cancer profiling. Its Guardant360 assay was developed to identify genomic alterations from blood samples and help oncologists evaluate targeted-treatment options. The platform also created a foundation for partnerships with pharmaceutical companies seeking biomarker data, clinical-trial support, and ways to study how tumors evolve during treatment. This dual focus on clinical diagnostics and biopharmaceutical services became a central feature of the company’s business model. The company expanded its oncology portfolio with products addressing treatment response and recurrence. Guardant360 Response was developed to evaluate molecular response during therapy, while Reveal was designed to detect circulating tumor DNA associated with residual disease and recurrence risk, including applications in colorectal cancer. These tests reflect a shift from simply identifying mutations to measuring disease dynamics over time. Guardant achieved a major regulatory milestone in 2020 when the FDA approved Guardant360 CDx as a companion diagnostic. The approval strengthened the company’s position in regulated precision oncology and supported the use of liquid biopsy in treatment selection for an indicated targeted therapy. Guardant continued to develop additional regulated and laboratory testing applications while expanding its relationships with drug developers and healthcare providers. A second major strategic direction was earlier detection. Guardant developed Shield as a blood-based colorectal-cancer screening test for adults at average risk. The program required clinical validation, regulatory review, and an effort to fit blood testing into established screening pathways that include colonoscopy and stool-based tests. In 2024, the FDA approved Shield, allowing the test to be marketed for colorectal-cancer screening in the indicated population. The approval gave Guardant an opportunity to address people who may not complete existing screening procedures, while also creating the responsibilities associated with false positives, follow-up colonoscopy, clinical integration, and reimbursement. Guardant became a public company in 2018, listing on Nasdaq as GH. Since then, its strategy has combined growth in oncology testing, commercialization of Shield, expansion of biopharmaceutical services, and continued investment in early-detection research. The company’s technology and data assets place it in competition with molecular-diagnostics, liquid-biopsy, and cancer-screening companies. Its long-term performance depends on evidence of clinical utility, regulatory clearances, payer coverage, physician adoption, test volumes, and the economics of operating high-complexity laboratory services. Today, Guardant Health is an independent public healthcare company headquartered in Palo Alto. It operates across advanced cancer genomic profiling, companion diagnostics, molecular response and recurrence monitoring, colorectal-cancer screening, and data-enabled services for pharmaceutical research.

2024
Shield approved for colorectal-cancer screening
[4]FDA approval of Shield colorectal-cancer screening testfda.gov
The FDA approved Shield, a blood-based test for colorectal-cancer screening in adults aged 45 and older at average risk.
2020
Guardant360 CDx approved by the FDA
[3]FDA approval of Guardant360 CDxfda.gov
The FDA approved Guardant360 CDx as a liquid-biopsy companion diagnostic and comprehensive genomic profiling test.
2018
Initial public offering
[5]Guardant Health initial public offering announcementinvestors.guardanthealth.com
Guardant Health completed its initial public offering and began trading on Nasdaq under GH.
2014
Guardant360 launched
[7]Guardant360 launchedguardanthealth.com
The company introduced Guardant360 as a blood-based comprehensive genomic profiling test for advanced cancer care.
2012
Guardant Health founded
[6]Guardant Health foundedguardanthealth.com
Helmy Eltoukhy and AmirAli Talasaz founded Guardant Health to develop blood-based genomic testing and liquid-biopsy applications.

Products and positioning

A precision-oncology and cancer-screening company using circulating tumor DNA, next-generation sequencing, and clinical data to support therapy selection, treatment monitoring, recurrence assessment, and earlier cancer detection.

Liquid-biopsy comprehensive genomic profiling · 2014
Guardant360
Guardant360 analyzes circulating tumor DNA from a blood sample to identify genomic alterations in advanced solid tumors. The test is intended to provide molecular information that can help inform treatment decisions, identify potential clinical-trial opportunities, and characterize tumor biology when tissue is unavailable or difficult to obtain.
FDA-approved companion diagnostic · 2020
Guardant360 CDx
Guardant360 CDx is the regulated version of Guardant’s liquid-biopsy platform used for comprehensive genomic profiling and selection of patients for specified targeted therapies. It combines genomic testing with a companion-diagnostic indication recognized by the FDA.
Treatment-response monitoring
Guardant360 Response
Guardant360 Response is designed to use circulating tumor DNA measurements to assess molecular response during cancer treatment. The product is intended to provide an earlier indication of whether a tumor is responding than conventional imaging alone in appropriate clinical and research contexts.
Molecular residual disease monitoring · 2021
Reveal
Reveal is a blood-based assay for detecting circulating tumor DNA after treatment, with applications including molecular residual disease and recurrence-risk assessment. It is primarily associated with colorectal-cancer monitoring and is used to add molecular information to conventional clinical follow-up.
Colorectal-cancer screening · 2024
Shield
Shield is a blood-based colorectal-cancer screening test for adults at average risk. It is intended to make screening more accessible through a blood draw, while positive results require follow-up diagnostic evaluation such as colonoscopy. The FDA approved the test in 2024.

Controversies

2022
Illumina files trade-secrets lawsuit against Guardant Health
Illumina filed a lawsuit against Guardant Health, alleging that Guardant's co-founders took confidential Illumina documents and that patents central to Guardant's cancer-detection work relied on that information. Guardant disputed Illumina's claims and said they had no merit.
Source

2024
Commercialization of Shield after FDA approvalProduct launch
Background
Guardant sought to extend liquid biopsy from advanced-cancer profiling into population screening, where convenience and accessibility could address participation gaps in colorectal-cancer screening.
Action taken
The FDA approved Shield for colorectal-cancer screening in average-risk adults aged 45 and older.
Aftermath
Guardant gained a regulated entry into a large screening market, while clinical adoption depends on follow-up care, payer coverage, physician workflows, and public-health guidance.
Source
2020
Pursuit of regulated companion-diagnostic statusProduct launch
Background
Liquid biopsy had been used in oncology, but regulatory approval as a companion diagnostic could strengthen clinical adoption and connect genomic testing directly to treatment selection.
Action taken
Guardant obtained FDA approval for Guardant360 CDx as a comprehensive genomic profiling test and companion diagnostic for an indicated targeted therapy.
Aftermath
The approval expanded the platform’s regulated role in precision oncology and supported further development of blood-based diagnostic applications.
Source
2018
Public listing to fund platform expansionStrategy
Background
Guardant had developed a commercial liquid-biopsy business and sought additional capital to expand laboratory capacity, clinical development, sales, and biopharmaceutical collaborations.
Action taken
The company completed an initial public offering and listed its common stock on Nasdaq under GH.
Aftermath
The listing gave Guardant access to public-market capital and increased reporting and investor obligations as it pursued oncology growth and early-detection programs.
Source

Recent events

2022.03.16
Reported2022.03.17
Illumina files trade-secrets lawsuit against Guardant Health[8]Illumina files trade-secrets lawsuit against Guardant Healthstatnews.com
Illumina filed a lawsuit against Guardant Health, alleging that Guardant's co-founders took confidential Illumina documents and that patents central to Guardant's cancer-detection work relied on that information. Guardant disputed Illumina's claims and said they had no merit.
2021.05.27
Reported2021.05.28
Guardant Health sues Natera over alleged advertising claims[9]Illumina files trade-secrets lawsuit against Guardant Healthlawstreetmedia.com
Guardant Health sued Natera, alleging that Natera ran a campaign of false and misleading advertising concerning Guardant's Reveal cancer assay and made unfounded comparisons with its own product. These are allegations in the lawsuit.
2020.08.07
Reported2020.08.07
FDA approves Guardant360 CDx for EGFR mutation identification[10]FDA批准Guardant360 CDx用于识别EGFR突变healio.com
The FDA approved Guardant360 CDx to identify EGFR mutations in patients with metastatic non-small cell lung cancer; the approval applies to this use, according to the article.

Sources11 sources

Cite this profile: Cite the canonical profile. /brand-wiki/guardant-health · Editorial policy · How profiles are compiled